How much profit has Addex Therapeutics made this year?
Addex Therapeutics has made -7.12 M CHF this year.
Addex Therapeutics Net Income 2024
Addex Therapeutics Net Income
-7.12 M CHF
Ticker
ADXN.SW
ISIN
CH0029850754
WKN
A0MSH6
In 2024, Addex Therapeutics's profit amounted to -7.12 M CHF, a -32.56% increase from the -10.56 M CHF profit recorded in the previous year.
The Addex Therapeutics Net Income history
| YEAR | NET INCOME (undefined CHF) |
|---|---|
| 2029e | - |
| 2028e | - |
| 2027e | - |
| 2026e | - |
| 2025e | - |
| 2024e | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
| 2010 | - |
| 2009 | - |
| 2008 | - |
| 2007 | - |
| 2006 | - |
| 2005 | - |
| 2004 | - |
Addex Therapeutics Revenue, EBIT, Net Income CH0029850754 · A0MSH6
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Addex Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Addex Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Addex Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Addex Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Addex Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Addex Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Addex Therapeutics’s growth potential.
Addex Therapeutics Revenue, EBIT and net profit per share
| Date | Addex Therapeutics Revenue | Addex Therapeutics EBIT | Addex Therapeutics Net Income |
|---|---|---|---|
| 2029e | 7.2 M undefined | 0 undefined | 0 undefined |
| 2028e | 4.15 M undefined | -7.99 M undefined | -3.88 M undefined |
| 2027e | 6.91 M undefined | -5.82 M undefined | 0 undefined |
| 2026e | 765,000 undefined | -3.37 M undefined | -5.46 M undefined |
| 2025e | 765,000 undefined | -3.88 M undefined | -6.62 M undefined |
| 2024e | 1.22 M undefined | -3.93 M undefined | -7.12 M undefined |
| 2023 | 1.65 M undefined | -10.28 M undefined | -10.56 M undefined |
| 2022 | 1.44 M undefined | -20.52 M undefined | -20.8 M undefined |
| 2021 | 3.15 M undefined | -15.51 M undefined | -15.2 M undefined |
| 2020 | 3.88 M undefined | -12.24 M undefined | -12.86 M undefined |
| 2019 | 2.83 M undefined | -14.6 M undefined | -14.78 M undefined |
| 2018 | 6.7 M undefined | -1.42 M undefined | -1.64 M undefined |
| 2017 | 499,890 undefined | -3.24 M undefined | -3.28 M undefined |
| 2016 | 399,960 undefined | -3.14 M undefined | -3.15 M undefined |
| 2015 | 392,020 undefined | -3.04 M undefined | -4.2 M undefined |
| 2014 | 726,570 undefined | -1.8 M undefined | -1.77 M undefined |
| 2013 | 140,000 undefined | -14.46 M undefined | -14.46 M undefined |
| 2012 | 120,000 undefined | -27.01 M undefined | -27.02 M undefined |
| 2011 | 3.74 M undefined | -30.97 M undefined | -31.14 M undefined |
| 2010 | 4 M undefined | -33.6 M undefined | -33.65 M undefined |
| 2009 | 4.5 M undefined | -43.05 M undefined | -42.69 M undefined |
| 2008 | 26.87 M undefined | -24.87 M undefined | -22.07 M undefined |
| 2007 | 640,000 undefined | -37.62 M undefined | -35.09 M undefined |
| 2006 | 4.78 M undefined | -20.9 M undefined | -20.54 M undefined |
| 2005 | 6.15 M undefined | -16.4 M undefined | -16.31 M undefined |
| 2004 | 200,000 undefined | -15 M undefined | -15.05 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 200,000 CHF | -15 M CHF | -15.05 M CHF |
| 2005 | 6.15 M CHF | -16.4 M CHF | -16.31 M CHF |
| 2006 | 4.78 M CHF | -20.9 M CHF | -20.54 M CHF |
| 2007 | 640,000 CHF | -37.62 M CHF | -35.09 M CHF |
| 2008 | 26.87 M CHF | -24.87 M CHF | -22.07 M CHF |
| 2009 | 4.5 M CHF | -43.05 M CHF | -42.69 M CHF |
| 2010 | 4 M CHF | -33.6 M CHF | -33.65 M CHF |
| 2011 | 3.74 M CHF | -30.97 M CHF | -31.14 M CHF |
| 2012 | 120,000 CHF | -27.01 M CHF | -27.02 M CHF |
| 2013 | 140,000 CHF | -14.46 M CHF | -14.46 M CHF |
| 2014 | 726,570 CHF | -1.8 M CHF | -1.77 M CHF |
| 2015 | 392,020 CHF | -3.04 M CHF | -4.2 M CHF |
| 2016 | 399,960 CHF | -3.14 M CHF | -3.15 M CHF |
| 2017 | 499,890 CHF | -3.24 M CHF | -3.28 M CHF |
| 2018 | 6.7 M CHF | -1.42 M CHF | -1.64 M CHF |
| 2019 | 2.83 M CHF | -14.6 M CHF | -14.78 M CHF |
| 2020 | 3.88 M CHF | -12.24 M CHF | -12.86 M CHF |
| 2021 | 3.15 M CHF | -15.51 M CHF | -15.2 M CHF |
| 2022 | 1.44 M CHF | -20.52 M CHF | -20.8 M CHF |
| 2023 | 1.65 M CHF | -10.28 M CHF | -10.56 M CHF |
| 2024e | 1.22 M CHF | -3.93 M CHF | -7.12 M CHF |
| 2025e | 765,000 CHF | -3.88 M CHF | -6.62 M CHF |
| 2026e | 765,000 CHF | -3.37 M CHF | -5.46 M CHF |
| 2027e | 6.91 M CHF | -5.82 M CHF | 0 CHF |
| 2028e | 4.15 M CHF | -7.99 M CHF | -3.88 M CHF |
| 2029e | 7.2 M CHF | 0 CHF | 0 CHF |
Addex Therapeutics stock margins CH0029850754 · A0MSH6
The Addex Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Addex Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Addex Therapeutics.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Addex Therapeutics's sales revenue. A higher gross margin percentage indicates that the Addex Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Addex Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Addex Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Addex Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Addex Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Addex Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Addex Therapeutics Margin History
| Addex Therapeutics Gross margin | Addex Therapeutics Profit margin | Addex Therapeutics EBIT margin | Addex Therapeutics Profit margin |
|---|---|---|---|
| 2029e | -912.14 % | 0 % | 0 % |
| 2028e | -912.14 % | -192.84 % | -93.62 % |
| 2027e | -912.14 % | -84.28 % | 0 % |
| 2026e | -912.14 % | -440 % | -714.36 % |
| 2025e | -912.14 % | -506.67 % | -865.1 % |
| 2024e | -912.14 % | -320.83 % | -581.65 % |
| 2023 | -912.14 % | -624.22 % | -640.91 % |
| 2022 | -912.14 % | -1,420.12 % | -1,439.78 % |
| 2021 | -306.66 % | -491.73 % | -481.97 % |
| 2020 | -167.31 % | -315.62 % | -331.48 % |
| 2019 | -912.14 % | -515.38 % | -521.61 % |
| 2018 | -912.14 % | -21.25 % | -24.54 % |
| 2017 | -912.14 % | -647.15 % | -656.23 % |
| 2016 | -912.14 % | -785.42 % | -787.43 % |
| 2015 | -912.14 % | -775.5 % | -1,072.45 % |
| 2014 | -912.14 % | -247.28 % | -244.28 % |
| 2013 | -912.14 % | -10,328.57 % | -10,328.57 % |
| 2012 | -958.33 % | -22,508.33 % | -22,516.67 % |
| 2011 | 13.37 % | -828.07 % | -832.62 % |
| 2010 | -10.5 % | -840 % | -841.25 % |
| 2009 | -21.78 % | -956.67 % | -948.67 % |
| 2008 | 82.58 % | -92.56 % | -82.14 % |
| 2007 | -290.63 % | -5,878.13 % | -5,482.81 % |
| 2006 | 51.46 % | -437.24 % | -429.71 % |
| 2005 | 66.34 % | -266.67 % | -265.2 % |
| 2004 | -580 % | -7,500 % | -7,525 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | -580 % | -7,500 % | -7,525 % |
| 2005 | 66.34 % | -266.67 % | -265.2 % |
| 2006 | 51.46 % | -437.24 % | -429.71 % |
| 2007 | -290.63 % | -5,878.13 % | -5,482.81 % |
| 2008 | 82.58 % | -92.56 % | -82.14 % |
| 2009 | -21.78 % | -956.67 % | -948.67 % |
| 2010 | -10.5 % | -840 % | -841.25 % |
| 2011 | 13.37 % | -828.07 % | -832.62 % |
| 2012 | -958.33 % | -22,508.33 % | -22,516.67 % |
| 2013 | -912.14 % | -10,328.57 % | -10,328.57 % |
| 2014 | -912.14 % | -247.28 % | -244.28 % |
| 2015 | -912.14 % | -775.5 % | -1,072.45 % |
| 2016 | -912.14 % | -785.42 % | -787.43 % |
| 2017 | -912.14 % | -647.15 % | -656.23 % |
| 2018 | -912.14 % | -21.25 % | -24.54 % |
| 2019 | -912.14 % | -515.38 % | -521.61 % |
| 2020 | -167.31 % | -315.62 % | -331.48 % |
| 2021 | -306.66 % | -491.73 % | -481.97 % |
| 2022 | -912.14 % | -1,420.12 % | -1,439.78 % |
| 2023 | -912.14 % | -624.22 % | -640.91 % |
| 2024e | -912.14 % | -320.83 % | -581.65 % |
| 2025e | -912.14 % | -506.67 % | -865.1 % |
| 2026e | -912.14 % | -440 % | -714.36 % |
| 2027e | -912.14 % | -84.28 % | 0 % |
| 2028e | -912.14 % | -192.84 % | -93.62 % |
| 2029e | -912.14 % | 0 % | 0 % |
Addex Therapeutics Aktienanalyse
What does Addex Therapeutics do?
Addex Therapeutics Ltd is a biotechnology company focused on the discovery and development of novel oral drugs. The company was founded in Geneva, Switzerland in 2002 and has made significant progress in researching drug candidates for various conditions such as schizophrenia, ADHD, migraines, and other central nervous system disorders. Addex Therapeutics' business model is based on the development of modulating therapeutics that specifically influence cellular signaling pathways. The company utilizes the proven AMC platform (Addex Modulation Cloning) to quickly and efficiently identify and validate specific receptor projects. Additionally, the company has a wide range of research and development programs, from preclinical to clinical study phases. Addex Therapeutics Ltd specializes in three therapeutic areas: neurological, immunological, and anti-inflammatory diseases. Within these areas, the company develops various drugs that specifically target certain receptors and provide help and relief for various conditions. One of Addex's most significant medical projects currently is the ADX71149 drug candidate for the treatment of schizophrenia and autism. Addex Therapeutics Ltd's products include a variety of neuromodulators and other drug candidates. The company has filed numerous international patents and maintains a high standard in the pharmaceutical development industry. The key product candidates are: - ADX10059: A new drug used in the treatment of migraines and dizziness. ADX10059 is a P2X3 receptor antagonist that can help suppress the transmission of pain signals in the central nervous system. - ADX88178: A drug candidate targeting the GABA-B receptor. This receptor is central to deep-seated pain and extrapyramidal side effects of classic antipsychotics. - ADX71943: A drug candidate used in the treatment of neuropsychiatric disorders such as Rett syndrome and ADHD. ADX71943 is a selective agonist of the GABA-B receptor, modulating the release of neurotransmitters in the brain. Overall, Addex Therapeutics offers an extensive product range and carries out a variety of projects in different stages of development. The company's core competency lies in modulators that can control specific receptors (neurotransmitter or hormone receptors). Addex Therapeutics Ltd is headquartered in Geneva, Switzerland, but also has branches in New York and San Francisco. The company focuses on expanding its competitiveness in the field of novel drugs and expanding its portfolio of products and international customers. Addex Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Addex Therapeutics's Profit Margins
The profit margins of Addex Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Addex Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Addex Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Addex Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Addex Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Addex Therapeutics stock
How has the profit developed compared to last year?
The profit has increased by -32.56% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Addex Therapeutics publish its earnings?
Addex Therapeutics publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Addex Therapeutics?
The profits of Addex Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Addex Therapeutics?
You can learn more about the earnings of Addex Therapeutics by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Addex Therapeutics pay?
Over the past 12 months, Addex Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Addex Therapeutics is expected to pay a dividend of 0 CHF.
What is the dividend yield of Addex Therapeutics?
The current dividend yield of Addex Therapeutics is .
When does Addex Therapeutics pay dividends?
Addex Therapeutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Addex Therapeutics?
Addex Therapeutics paid dividends every year for the past 0 years.
What is the dividend of Addex Therapeutics?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is Addex Therapeutics located?
Addex Therapeutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Addex Therapeutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Addex Therapeutics from 9/11/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 9/11/2024.
When did Addex Therapeutics pay the last dividend?
The last dividend was paid out on 9/11/2024.
What was the dividend of Addex Therapeutics in the year 2023?
In the year 2023, Addex Therapeutics distributed 0 CHF as dividends.
In which currency does Addex Therapeutics pay out the dividend?
The dividends of Addex Therapeutics are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Addex Therapeutics
Our stock analysis for Addex Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Addex Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Addex Therapeutics Revenue
- Addex Therapeutics Net Income
- Addex Therapeutics P/E
- Addex Therapeutics P/S
- Addex Therapeutics EBIT
- Addex Therapeutics Dividend
- Addex Therapeutics Stocks
- Addex Therapeutics Market capitalization
- Addex Therapeutics Debt
- Addex Therapeutics Liabilities
- Addex Therapeutics Equity
- Addex Therapeutics AAQS
- Addex Therapeutics Employees
- Addex Therapeutics ROE
- Addex Therapeutics ROA
- Addex Therapeutics ROCE
